Lunai Bioworks Inc. (NASDAQ:LNAI) Short Interest Down 86.1% in May

Lunai Bioworks Inc. (NASDAQ:LNAI) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 345,109 shares, a decline of 86.1% from the May 14th total of 2,489,634 shares. Based on an average trading volume of 217,022 shares, the days-to-cover ratio is presently 1.6 days. Currently, 7.7% of the company’s shares are sold short.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LNAI shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Friday, April 10th. Wall Street Zen upgraded shares of Lunai Bioworks to a “sell” rating in a report on Saturday, May 23rd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Lunai Bioworks presently has an average rating of “Sell”.

Hedge Funds Weigh In On Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC acquired a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned about 0.87% of Lunai Bioworks as of its most recent SEC filing. 71.41% of the stock is owned by institutional investors and hedge funds.

Lunai Bioworks Price Performance

LNAI traded down $0.03 on Wednesday, hitting $2.26. The company had a trading volume of 24,704 shares, compared to its average volume of 1,551,275. Lunai Bioworks has a 52-week low of $1.21 and a 52-week high of $33.50. The stock has a fifty day simple moving average of $2.63 and a 200-day simple moving average of $5.07. The firm has a market capitalization of $10.24 million, a P/E ratio of -5.65 and a beta of 0.40.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.80) EPS for the quarter. The business had revenue of $0.02 million for the quarter.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.